T-cell receptor (TCR) and B-cell receptor (BCR) repertoire profiling holds great potential for understanding the disease mechanisms and development of new therapeutics for infectious disease, auto-immunity and immuno-oncology applications. However, this potential could be greatly improved by combining information about receptor clonotypes with immunophenotypes of T and B cells. To facilitate these studies, we developed a novel technology for combined profiling of all human TCR and BCR variable regions and phenotypic characterization of immune cells.
The developed TCR/BCR Immunophenotyping method involves multiplex RT-PCR amplification and sequencing of complementarity-determining regions (CDR) of TCR and BCR genes and a set of the most informative T- and B-cell phenotyping genes. Bioinformatics analysis of NGS data allows for the profiling of TCR/BCR clonotypes, as well as identifying major immune cell subtypes and their activation status.
Register for this webinar to see data showing how combined TCR/BCR clonotype analysis combined with targeted expression profiling of immune cells can be applied for large-scale discovery of novel cell typing and activation biomarkers in several immune-response model systems. Preliminary studies indicate the assay has unparalleled throughput, sensitivity and improved cost-effectiveness for high-throughput immunity biomarker discovery applications.
Alex Chenchik, PhD, President and Chief Scientific Officer, Cellecta, Inc.
Dr. Alex Chenchik is president and chief scientific officer of Cellecta, Inc. based in Mountain View, California. Cellecta is focused on the development and application of next generation functional genomic technologies for the discovery of biomarkers, drug targets and the development of novel drugs. While at System Biosciences (SBI) as vice president of R&D, he developed a genetic screen technology with pooled lentiviral shRNA libraries in combination with a wide range of reporter cell lines. As director of the Gene Cloning and Analysis (GCA) group at Clontech Laboratories, he headed efforts to develop microarray and disease-profiling arrays for expression profiling, PCR-based technologies for gene cloning, and a subtraction-based approach for discovery of differentially expressed genes. Dr. Chenchik received his doctorate in Molecular Biology from the Institute of Molecular Biology, Moscow, Russia, and was a research scientist at the National Cardiology Research Center in Moscow. He has authored over 50 publications and is an inventor with more than a dozen issued patents.Message Presenter
Paul Diehl, Ph.D., Chief Operating Officer, Cellecta, Inc.
Dr. Paul Diehl joined Cellecta, Inc. in July 2010 where he applies over two decades of experience in biotechnology to developing and expanding the company’s commercial and collaborative activities. Prior to joining Cellecta, Dr. Diehl held various marketing and business development positions at B-Bridge International, Agilent Technologies, Clontech Laboratories and other companies. Dr. Diehl received his B.A. in Biology from LaSalle University in Philadelphia, PA and his Ph.D. in Biochemistry from Washington State University in Pullman, WA.Message Presenter
Who Should Attend?
Pharma, Biotech, Government, Academic Medical Centers:
- Research Scientists, Associates, Assistants
- Senior or Principal Researcher
- Senior or Principal Investigator
- Senior or Principal Scientist
- Drug Discovery and Validation Scientist
- Pre-clinical Scientist
- Director, R&D
What You Will Learn
- The importance of TCR and BCR repertoire profiling for understanding mechanisms of action
- The value of combining information about receptor clonotypes with immunophenotypes of T and B cells
- The potential application of this methodology for large-scale discovery of novel cell typing and activation biomarkers
A brief overview of Cellecta technologies will follow the main presentation
Cellecta is a trusted provider of functional genomic products and services with over 15 years’ experience working with the world’s leading pharma, biotech, and academic institutions. Our portfolio includes products and services for loss-of-function and gain-of-function phenotypic screening, cell barcoding and gene expression profiling. This includes design and manufacture of custom and genome-wide CRISPR and RNAi libraries, lentiviral constructs and cell engineering services. We also offer expression profiling assays and spatial transcriptomic services for drug target and biomarker discovery and other applications.